OBESIAL

RecruitingPhase NA

OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme

Lead sponsor

University of Health Sciences, Algeria

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Estimated enrollment

300

Study population

Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥30

Primary endpoint

•≥5% Weight Loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07779343

Org study IDOBESIAL

Secondary IDMCHA-MED-2026/01Mother and Child hospital of the Army

Timeline

Milestones

Study start2026-01-22actual

Study first posted2026-08-21actual

Last update posted2026-08-21actual

Primary completion2028-01-23estimated

Study completion2028-01-23estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Adults aged 18-65 years

•BMI ≥30 kg/m²

•Written informed consent obtained prior to enrolment

Exclusion criteria

•Refusal to participate or inability to adhere to follow-up procedures

•Pregnancy at enrolment

•Severe or unstable comorbidities compromising safety or participation, including:

-Recent acute cardiovascular event (<60 days)

-Active malignancy

-Severe unstable organic disease

•Previous bariatric surgery

•Obesity pharmacotherapy within the previous 90 days

•Known contraindication to planned therapeutic options

•Severe unstable psychiatric disorders

•Genetic obesity or obesity secondary to uncontrolled endocrine disease

Exclusion Criteria During Follow-up

•Pregnancy occurring during follow-up

•Initiation of chronic treatment associated with weight gain

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Cardiometabolic biomarkers

Weight & body composition

6 endpoints

Primary/protocol endpoint

Percentage of Participants Achieving ≥5% Weight Loss at Month 18

Time frame:18 months follow-up

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of participants achieving ≥5% weight loss from randomization baseline at Month 18

Time frame:From Month 6 to Month 18

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of participants achieving ≥10% weight loss from randomization baseline at Month 18

Time frame:From Month 6 to Month 18

threshold achievement, improvement

Secondary/protocol endpoint

Proportion of participants achieving ≥15% weight loss from randomization baseline at Month 18

Time frame:From Month 6 to Month 18

threshold achievement, improvement

Secondary/protocol endpoint

Baseline predictors of weight loss response to semaglutide at Month 18

Time frame:From Month 6 to Month 18

descriptive

Secondary/protocol endpoint

Change in body composition from baseline to Month 18

Time frame:Months 0, 6, 12, and 18; change from Month 0 to Month 18 for G1 versus G2 and from Month 6 to Month 18 for G1a versus G1b

change from baseline, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Change in glycemic parameters from baseline to Month 18

Time frame:Baseline (Month 0) to Month 18 for the G1 versus G2. Month 6 to Month 18 for the G1a versus G1b

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

Change in lipid parameters from baseline to Month 18

Time frame:Baseline (Month 0) to Month 18 for the G1 versus G2.Month 6 to Month 18 for the G1a versus G1b.

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.